Fig. 4.

Lack of IL-13-mediated signalling does not abrogate the increase in AOM-mediated ACF development in IL-4Rα^−/− mice compared with WT animals. (A) The number of ACFs per colon 6 weeks after sham or AOM treatment in WT, IL-13 ^−/−, IL-4Rα ^−/− and IL-4Rα ^−/− × IL-13 ^−/− DKO mice. Data are from individual mice. Bars represent the median value for each group. The number of mice within each group is noted below the treatment group labels. (B) ACF size (measured as the number of abnormal crypts in each ACF) in WT, IL-13 ^−/−, IL-4Rα ^−/− and DKO mice 6 weeks after AOM administration. There was no significant difference between the genotypes (Kruskal–Wallis test followed by Dunn’s multiple comparison test).